Anne-Marie Ronchetti, Christophe Leboeuf, Emmanuel Raffoux, Dominique Bories, Nathalie Dhedin, Etienne Lengline, Nicolas Boissel, Regis Peffault de Latour, Hervé Dombret, Anne Janin, Gerard Socié and Thomas Cluzeau
We report here the first clinical case of GvL post Blinatumomab treatment in acute lymphoblastic leukemia relapsing after allo stem cell transplantation. This effects accompanied a skin GvHD and has been documented by skin biopsy, immune-staining and FISH. We thus hypothesize that the GvHD may have contributed to disease eradication in this patient, the allogeneic setting reinforcing the immunological efficacy of blinatumomab through a GvL effect. Blinatumomab could actually represent a very interesting therapeutic approach in relapse and/or in prevention of relapse after alloSCT.